ASCO GUIDELINES Bundle

Immune-related Adverse Events CAR T-Cell Therapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475467

Contents of this Issue

Navigation

Page 13 of 15

14 Management Table 7. Infections Workup/Evaluation: • History and physical exam • Full blood count • Bacterial cultures and evaluation for other infection (fungal, viral) Grading Management All Grades • Antiviral and PJP prophylaxis per institutional standards, for 6–12 months following CAR T-cell infusion and/or until CD4 cell count is >200 cells/ul. • Antifungal agents should be considered for high- risk patients. • G-CSF should be considered in patients after CRS with >7 days of neutropenia. G1: Mild infection only • Offer supportive care. • Empiric antimicrobials (antibiotics such as levofloxacin or ciprofloxacin, antifungals such as fluconazole or antivirals such as valacyclovir or acyclovir) should be considered upon onset of fever. G2: Mild infection; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral) • Start course of oral antimicrobials. G3: Severe infection; IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated • Start IV antimicrobials. G4: Life-threatening consequences; urgent intervention indicated • Critical care support.

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Immune-related Adverse Events CAR T-Cell Therapy